871673-24-4 Usage
Uses
Used in Pharmaceutical Development:
3-AMINO-N-CYCLOPROPYLBENZAMIDE is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the creation of novel compounds with potential therapeutic applications, making it a valuable asset in drug discovery and development processes.
Used in Agrochemical Synthesis:
In the agrochemical industry, 3-AMINO-N-CYCLOPROPYLBENZAMIDE serves as a building block for the development of new agrochemicals. Its incorporation into these compounds can lead to enhanced crop protection and management solutions, contributing to improved agricultural practices.
Used in Cancer Research:
3-AMINO-N-CYCLOPROPYLBENZAMIDE is explored as a potential therapeutic agent in cancer research. Its specific properties may contribute to the development of treatments targeting various types of cancer, offering new avenues for cancer therapy.
Used in Neurological Disorder Research:
3-AMINO-N-CYCLOPROPYLBENZAMIDE is also under investigation for its potential role in the treatment of neurological disorders. Its unique structure and functional groups may provide insights into the development of new treatments for conditions affecting the nervous system.
Check Digit Verification of cas no
The CAS Registry Mumber 871673-24-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,1,6,7 and 3 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 871673-24:
(8*8)+(7*7)+(6*1)+(5*6)+(4*7)+(3*3)+(2*2)+(1*4)=194
194 % 10 = 4
So 871673-24-4 is a valid CAS Registry Number.
871673-24-4Relevant academic research and scientific papers
Targeting the Kv11.1 (hERG) channel with allosteric modulators. Synthesis and biological evaluation of three novel series of LUF7346 derivatives
van Veldhoven, Jacobus P.D.,Campostrini, Giulia,van Gessel, Constantijn J.E.,Ward-van Oostwaard, Dorien,Liu, Rongfang,Mummery, Christine L.,Bellin, Milena,IJzerman, Adriaan P.
, (2020/12/07)
We synthesized and evaluated three novel series of substituted benzophenones for their allosteric modulation of the human Kv11.1 (hERG) channel. We compared their effects with reference compound LUF7346 previously shown to shorten the action po
Pyrrolo[3,2-b ]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: Structure-based design, synthesis, and in vivo validation
Unzue, Andrea,Dong, Jing,Lafleur, Karine,Zhao, Hongtao,Frugier, Emilie,Caflisch, Amedeo,Nevado, Cristina
supporting information, p. 6834 - 6844 (2014/10/15)
The X-ray crystal structures of the catalytic domain of the EphA3 tyrosine kinase in complex with two type I inhibitors previously discovered in silico (compounds A and B) were used to design type I1/2 and II inhibitors. Chemical synthesis of a
